Clinical and immune relationships and treatment pattern in HIVinfected schizophrenic patients
Suggested citation:
Polyanskiy DA, Kalinin VV. [Clinical and immune relationships and treatment pattern in HIVinfected schizophrenic patients]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2017;(3):33-40. Russian
The current study has been carried out in order to evaluate the possible discrepancies in psychopathological symptoms in HIV-infected and non-infected schizophrenic patients. Forty HIV-infected patients with verified diagnosis of schizophrenia were included into study. Among studied patients were 23 females (58%) and 17 males (42%). Forty patients with schizophrenia without HIV is control group (23 females, 48% and 21 males (52%). In study use clinical and psychopathological method, immunity was assessed by use of flowing cytometriya. Results: The statistically significant positive correlation between CD3+CD4+ T-lymphocyte count and daily dose of zuclopenthixol has been revealed. On the other hand, the inverse correlation between CD3+ CD4+ T-lymphocyte count in blood and daily dose of clozapine has been obtained. The mean daily dose of clozapine used to relieve the psychotic states in HIV-infected group was much less than in control group
1. Adler M.W. ABC of AIDS. Development of the epidemic. British Medical Journal. 1987; 294 (6579):1083-5. 2. Lishman’s organic psychiatry: a textbook of neuropsychiatry/ David A.S., Fleminger S., Kopelman M.D., Lovestone S., Mellers J.D.S. 4th Edition. Willey-Blackwell. A J. Willey & Sons Ltd, Chichester, W. Sussex, UK. 2009;2,ch.7:397-472. 3. Querques J., Freudenreich O. Psychiatric aspects of HIV infection and AIDS. In: Stern T.A., Fava M., Wilens T.E., Rosenbaum J.F. Massachusetts General Hospital. Comprehensive Clinical Psychiatry (Second Edition. Elsevier). 2016; 57:627-37. 4. Poljanskij D.A., Kalinin V.V., Mazus A.I., Ol'shanskij A.Ja. Immunologicheskie i kliniko-psihopatologicheskie sootnoshenija u VICh-inficirovannyh bol'nyh shizofreniej. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2013;113(11-1):74-7. 5. Poljanskij D.A., Kalinin V.V., Ol'shanskij A.Ja., Naryshkin A.V., Holodov Je.Ju. Prognoz immunologicheskogo statusa u VICh-inficirovannyh bol'nyh shizofreniej po psihopatologicheskim dannym. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2015;115(5):76-81. 6. Poljanskij D.A., Kalinin V.V., Ol'shanskij A.Ja. Vzaimosvjazi immunologicheskih i psihopatologicheskih harakteristik VICh-inficirovannyh bol'nyh shizofreniej. Zhurnal Social'naja i klinicheskaja psihiatrija. 2016;26(3):17-24. 7. McAlister C.G., Rapaport M.H., Pickar D., Paul S.M. Effects of Short-term Administration of Antipsychotic Drugs on Lymphocyte Subsets in Schizophrenic Patients. Archives of General Psychiatry. 1989;46(10):956-7. 8. Zarrabi M.H., Zucker S., Miller F., Derman R.M., Romano G.S., Hartnett J.A., Varma A.O. Immunologic and Coagulation Disorders in Chlorpromazine-Treated Patients. Annals of Internal Medicine. 1979;91(2):194-9 9. Maes M., Chiavetto L.B, Bignotti S., Tura G-J.B., Pioli R., Boin F., Kenis G., Bosmans E., De Jongh R., Lin A., Racagni G., Altamura C.A. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European Neuropsychopharmacology. 2000;10(2):119-24. 10. Whatley S.A., Curti D., Das Gupta F., Ferrier I.N., Jones S., Taylor C., Marchbanks R.M. Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients. Molecular Psychiatry. 1998;3(3):227-37. 11. Baskak B., Ozel E.T., Atbasoglu C., Baskak S.C. Peculiar word use as a possible trait marker in schizophrenia. Schizophrenia Research. 2008;103(1-3):311-7. 12. Hennederg A., Riedl H., Dumke H-O., Kornhuber H.H. T-lymphocyte subpopulations in schizophrenia patients. European Archives of Psychiatry and Neurological. 1990; 239(5):283-4. 13. Sperner-Unterweger B., Whitworth A., Kemmler G., Hilbe W., Thaler J., Weiss G., Fleischhacker W.W. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophrenia. 1999;38(1):61-70.. 14. Theodoropoulou S., Spanakos G., Baxcvanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., Stefanis C.N. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophrenia Research. 2001;47(1):13-25. 15. Detting M., Schaub R., Muller-Oerlinghausen B., Roots I., Cascorbi I. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics. 2001;11(2):135-141. 16. Zvara A., Szekeres G., Janka Z., Kelemen J.Z., Cimmer C., Sántha M., Puskás L.G. Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in druge-naive schizophrenic peripheral blood lymphocites as potencial diagnostic markers. Disease Markers. 2005;21(2):61-9. 17. Dunbar N., Brew B.J. Neuropsychological dysfunction in HIV infection. Journal of Neuro-AIDS. 1996;1(3):73-102. 18. De Ronchi D., Faranca I., Forti P., Ravaglia G., Borderi M., Manfredi R., Volterra V. Development of acute psychotic disorders and HIV-1 infection. International Journal of Psychiatry in Medicine. 2000;30(2):173-183. 19. Petrie A.A. The Prognosis in Schizophrenia and the Factors Influencing the Course of the Disease: By Gabriel Langfeldt, M.D., The University Clinic, Vinderen, near Oslo. Copenhagen: Levin & Munksgaard, Ejnar Munksgaard, 1937. The British Journal of Psychiatry. 1939;85(356):573. 20. Langfeldt G. Schizophrenia: Diagnosis and prognosis. Behavioral Science. 1969;14(3):173-82. 21. Petrilowitsch N. Die Schizophrenien in strukturpsychiatrisher Sicht. Psychopathology. 1969;2(5):289-306. 22. Nemcov A.B., Kalinin V.V., Zajcev S.G. Prognoz jeffektivnosti farmakoterapii bol'nyh ostroj shizofreniej na osnove korreljacionnogo i regressionnogo analiza klinicheskih i jelektrojencefalograficheskih pokazatelej. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 1982;9:1348-53. 23. Foster R., Olajide D., Everall I.P. Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Medicine. 2003;4(2):139-44. 24. Maschke M., Kastrup O., Esser S., Ross B., Hengge U., Hufnagel A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). Journal of Neurology, Neurosurgery and Psychiatry. 2000;69(3):376-80.
DOI: http://dx.doi.org/10.24411/1560-957X-2017-1%25x
Article Metrics
Metrics powered by PLOS ALM